STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...
The parkinsonian variant of multiple system atrophy (MSA-P) can be difficult to differentiate from Parkinson's disease (PD). This Practice Point commentary discusses a multicenter study performed by ...
A pilot study conducted by the Northern Territory Department of Primary Industry (DPIF) and Perth's Murdoch University has revealed a Meat Standards Australia (MSA) non-compliance rate of 70 per cent ...
Multiple system atrophy (MSA) is a sporadic and rare neurodegenerative movement disorder with an estimated annual incidence of 0.6 per 100,000 (ORPHA102) The clinical presentation is highly variable, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback